New antifungal antibiotics

Current Opinion in Infectious Diseases

Volumn 26, Issue 2, 2013, Pages 168-174

  Paiva, José A ^a   Pereira, José M ^a  

^a UNIVERSITY OF PORTO   (Portugal)

Author keywords

Antifungal agents; Echinocandins; Invasive fungal infections; Iron chelators; Nikkomycins; Respiratory infections; Triazoles

Indexed keywords

ALBACONAZOLE; AMPHOTERICIN B LIPID COMPLEX; ANTIFUNGAL AGENT; ASTEMIZOLE; BARBITURIC ACID DERIVATIVE; BENZODIAZEPINE DERIVATIVE; CALCIUM CHANNEL BLOCKING AGENT; CARBAMAZEPINE; CISAPRIDE; CYCLOSPORIN; DEFERASIROX; ECHINOCANDIN; ENFUMAFUNGIN; FLUCONAZOLE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ISAVUCONAZOLE; MICAFUNGIN; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; OMEPRAZOLE; POSACONAZOLE; RAVUCONAZOLE; RIFABUTIN; RIFAMPICIN; SULFONYLUREA DERIVATIVE; TACROLIMUS; TERFENADINE; TRIAZOLE DERIVATIVE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VORICONAZOLE; WARFARIN;

ANTIFUNGAL ACTIVITY; ANTIMICROBIAL THERAPY; AREA UNDER THE CURVE; ASPERGILLOSIS; CANDIDA; CANDIDEMIA; CANDIDIASIS; CHEMOPROPHYLAXIS; CHILL; COCCIDIOIDOMYCOSIS; DIARRHEA; DRUG ABSORPTION; DRUG CONTRAINDICATION; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG ELIMINATION; DRUG ERUPTION; DRUG FEVER; DRUG HALF LIFE; DRUG INDICATION; DRUG INDUCED HEADACHE; DRUG METABOLISM; ESOPHAGUS CANDIDIASIS; FUSARIOSIS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; INFECTION PREVENTION; INFUSION RELATED REACTION; INVASIVE ASPERGILLOSIS; INVASIVE CANDIDIASIS; LOADING DRUG DOSE; MINIMUM INHIBITORY CONCENTRATION; MUCOCUTANEOUS CANDIDIASIS; MUCORMYCOSIS; MYCOSIS; NAUSEA; NONHUMAN; OPPORTUNISTIC INFECTION; PHASE 2 CLINICAL TRIAL (TOPIC); PSEUDALLESCHERIASIS; REVIEW; SINGLE DRUG DOSE; TOXIC HEPATITIS; VOMITING; ZYGOMYCOSIS;

ANTIFUNGAL AGENTS; ECHINOCANDINS; HUMANS; LUNG DISEASES, FUNGAL; MYCOSES; TRIAZOLES;

EID: 84874932770     PISSN: 09517375     EISSN: 14736527     Source Type: Journal    
DOI: 10.1097/QCO.0b013e32835ebcb7     Document Type: Review

References (83)

1. Vincent JL, Rello J, Marshall J, et al. International study of the prevalence and outcomes of infection in intensive care units. JAMA 2009; 302:2323-2329.
2. Pagano L, Caira M, Candoni A, et al. The epidemiology of fungal infections in patients with hematologic malignancies: the SEIFEM-2004 study. Haematologica 2006; 91:1068-1075. (Pubitemid 44208634)
3. Chamilos G, Lewis RE, Kontoyiannis DP. Delaying amphotericin B-based frontline therapy significantly increases mortality among patients with hematologic malignancy who have zygomycosis. Clin Infect Dis 2008; 47:503-509.
4. Park BJ, Pappas PG, Wannemuehler KA, et al. Invasive non-Aspergillus mold infections in transplant recipients, United States, 2001-2006. Emerg Infect Dis 2011; 17:1855-1864.
5. Mohr J, Johnson M, Cooper T, et al. Current options in antifungal pharmacotherapy. Pharmacotherapy 2008; 28:614-645. (Pubitemid 351620030)
6. Andes D. Clinical utility of antifungal pharmacokinetics and pharmacodynamics. Curr Opin Infect Dis 2004; 17:533-540. (Pubitemid 39627514)
7. Andes D, Marchillo K, Stamstad T, Conklin R. In vivo pharmacokinetics and pharmacodynamics of a new triazole, voriconazole, in a murine candidiasis model. Antimicrob Agents Chemother 2003; 47:3165-3169. (Pubitemid 37229574)
8. Andes D, Marchillo K, Stamstad T, Conklin R. In vivo pharmacodynamics of a new triazole, ravuconazole, in a murine candidiasis model. Antimicrob Agents Chemother 2003; 47:1193-1199. (Pubitemid 36368574)
9. Andes D, van Ogtrop M. Characterization and quantitation of the pharmacodynamics of fluconazole in a neutropenic murine disseminated candidiasis infection model. Antimicrob Agents Chemother 1999; 43:2116-2120. (Pubitemid 29421186)
10. Andes D. Pharmacokinetics and pharmacodynamics of antifungals. Infect Dis Clin North Am 2006; 20:679-697. (Pubitemid 44375115)
11. Lass-Flörl C, Mayr A, Perkhofer S, et al. Activities of antifungal agents against yeasts and filamentous fungi: assessment according to the methodology of the European Committee on Antimicrobial Susceptibility Testing. Antimicrob Agents Chemother 2008; 52:3637-3641.
12. Vfend [package insert]. New York: Pfizer Inc.; 2010.
13. Groll AH, Gea-Banacloche JC, Glasmacher A, et al. Clinical pharmacology of antifungal compounds. Infect Dis Clin North Am 2003; 17:159-191. (Pubitemid 36514575)
14. Dodds-Ashley E. Management of drug and food interactions with azole antifungal agents in transplant recipients. Pharmacotherapy 2010; 30:842-854.
15. Bland SE. Voriconazole. J Pharm Soc Wisconsin 2002; 32-42.
16. Trotman RL, Williamson JC, Shoemaker DM, Salzer WL. Antibiotic dosing in critically ill adult patients receiving continuous renal replacement therapy. Clin Infect Dis 2005; 41:1159-1166. (Pubitemid 41429480)
17. Desta Z, Zhao X, Shin JG, Flockhart DA. Clinical significance of the cytochrome P450 2C19 genetic polymorphism. Clin Pharmacokinet 2002; 41:913-958. (Pubitemid 35168437)
18. Matsumoto K, Ikawa K, Abematsu K, et al. Correlation between voriconazole trough plasma concentration and hepatotoxicity in patients with different CYP2C19 genotypes. Int J Antimicrob Agents 2009; 34:91-94.
19. Pascual A, Calandra T, Bolay S, et al. Voriconazole therapeutic drug monitoring in patients with invasive mycoses improves efficacy and safety outcomes. Clin Infect Dis 2008; 46:201-211. (Pubitemid 351269158)
20. Walsh TJ, Anaissie EJ, Denning DW, et al. Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America. Clin Infect Dis 2008; 46:327-360. (Pubitemid 351265310)
21. Ezzet F, Wexler D, Courtney R, et al. Oral bioavailability of posaconazole in fasted healthy subjects: comparison between three regimens and basis for clinical dosage recommendations. Clin Pharmacokinet 2005; 44:211-220. (Pubitemid 40188942)
22. Noxafil [package insert]. Kenilworth, NJ: Schering-Plough; 2009.
23. Courtney R, Radwanski E, Lim J, Laughlin M. Pharmacokinetics of posaconazole coadministered with antacid in fasting or nonfasting healthy men. Antimicrob Agents Chemother 2004; 48:804-808. (Pubitemid 38280328)
24. Courtney R, Wexler D, Radwanski E, et al. Effect of food on the relative bioavailability of two oral formulations of posaconazole in healthy adults. Br J Clin Pharmacol 2004; 57:218-222. (Pubitemid 38223535)
25. Krishna G, Moton A, Ma L, et al. Pharmacokinetics and absorption of posaconazole oral suspension under various gastric conditions in healthy volunteers. Antimicrob Agents Chemother 2009; 53:958-966.
26. Sansone-Parsons A, Krishna G, Calzetta A, et al. Effect of a nutritional supplement on posaconazole pharmacokinetics following oral administration to healthy volunteers. Antimicrob Agents Chemother 2006; 50:1881-1883.
27. Nivoix Y, Ubeaud-Sequier G, Engel P, et al. Drug-drug interactions of triazole antifungal agents in multimorbid patients and implications for patient care. Curr Drug Metab 2009; 10:395-409.
28. Keating GM. Posaconazole. Drugs 2005; 65:1553-1567; discussion 1568-1569. (Pubitemid 41124308)
29. Wexler D, Courtney R, Richards W, et al. Effect of posaconazole on cytochrome P450 enzymes: a randomized, open-label, two-way crossover study. Eur J Pharm Sci 2004; 21:645-653. (Pubitemid 38447146)
30. Gubbins PO, Krishna G, Sansone-Parsons A, et al. Pharmacokinetics and safety of oral posaconazole in neutropenic stem cell transplant recipients. Antimicrob Agents Chemother 2006; 50:1993-1999. (Pubitemid 43807517)
31. Ullmann AJ, Cornely OA, Burchardt A, et al. Pharmacokinetics, safety, and efficacy of posaconazole in patients with persistent febrile neutropenia or refractory invasive fungal infection. Antimicrob Agents Chemother 2006; 50:658-666. (Pubitemid 43190980)
32. Thompson GR 3rd, Rinaldi MG, Pennick G, et al. Posaconazole therapeutic drug monitoring: a reference laboratory experience. Antimicrob Agents Chemother 2009; 53:2223-2224.
33. Kohl V, Muller C, Cornely A, et al. Factors influencing pharmacokinetics of prophylactic posaconazole in patients undergoing allogeneic stem cell transplantation. Antimicrob Agents Chemother 2010; 54:207-212.
34. Krishna G, Parsons A, Kantesaria B, Mant T. Evaluation of the pharmacokinetics of posaconazole and rifabutin following coadministration to healthy men. Curr Med Res Opin 2007; 23:545-552. (Pubitemid 46456902)
35. Warn PA, Sharp A, Denning DW. In vitro activity of a new triazole BAL4815, the active component of BAL8557 (the water-soluble prodrug), against Aspergillus spp. J Antimicrob Chemother 2006; 57:135-138. (Pubitemid 43057070)
36. Guinea J, Pelaez T, Recio S, et al. In vitro antifungal activities of isavuconazole (BAL4815), voriconazole, and fluconazole against 1,007 isolates of zygomycete, Candida, Aspergillus, Fusarium, and Scedosporium species. Antimicrob Agents Chemother 2008; 52:1396-1400. (Pubitemid 351522004)
37. Seifert H, Aurbach U, Stefanik D, Cornely O. In vitro activities of isavuconazole and other antifungal agents against Candida bloodstream isolates. Antimicrob Agents Chemother 2007; 51:1818-1821. (Pubitemid 46744163)
38. Perkhofer S, Lechner V, Lass-Florl C. In vitro activity of isavuconazole against Aspergillus species and Zygomycetes according to the methodology of the European committee on antimicrobial susceptibility testing. Antimicrob Agents Chemother 2009; 53:1645-1647.
39. Schmitt-Hoffmann A, Roos B, Heep M, et al. Single-ascending-dose pharmacokinetics and safety of the novel broad-spectrum antifungal triazole BAL4815 after intravenous infusions (50, 100, and 200 milligrams) and oral administrations (100, 200, and 400 milligrams) of its prodrug, BAL8557, in healthy volunteers. Antimicrob Agents Chemother 2006; 50:279-285. (Pubitemid 43042933)
40. Girmenia C. New generation azole antifungals in clinical investigation. Expert Opin Investig Drugs 2009; 18:1279-1295.
41. Schmitt-Hoffmann A, Roos B, Spickermann J, et al. Effect of mild and moderate liver disease on the pharmacokinetics of isavuconazole after intravenous and oral administration of a single dose of the prodrug BAL8557. Antimicrob Agents Chemother 2009; 53:4885-4890.
42. Viljoen JJ, Mitha I, Heep M, Ghannoum M. Efficacy, safety, and tolerability of three different dosing regimens of BAL8557 vs. fluconazole in a double-blind, randomized, multicenter trial for the treatment of esophageal candidiasis in immunocompromised adults [abstract]. In: Program and abstracts of the 45th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC); 16-19 December 2005; Washington, DC. American Society for Microbiology; 2005: abstr. LB2-32.
43. Baddley JW, Marr KA, Andes DR, et al. Patterns of susceptibility of Aspergillus isolates recovered from patients enrolled in the Transplant-Associated Infection Surveillance Network. J Clin Microbiol 2009; 47:3271-3275.
44. Diekema DJ, Messer SA, Hollis RJ, et al. Activities of caspofungin, itraconazole, posaconazole, ravuconazole, voriconazole, and amphotericin B against 448 recent clinical isolates of filamentous fungi. J Clin Microbiol 2003; 41:3623-3626. (Pubitemid 36994692)
45. Cuenca-Estrella M, Gomez-Lopez A, Mellado E, et al. In vitro activity of ravuconazole against 923 clinical isolates of nondermatophyte filamentous fungi. Antimicrob Agents Chemother 2005; 49:5136-5138. (Pubitemid 41778934)
46. Alastruey-Izquierdo A, Cuenca-Estrella M, Monzon A, et al. Antifungal susceptibility profile of clinical Fusarium spp. isolates identified by molecular methods. J Antimicrob Chemother 2008; 61:805-809. (Pubitemid 351426063)
47. Carrillo AJ, Guarro J. In vitro activities of four novel triazoles against Scedosporium spp. Antimicrob Agents Chemother 2001; 45:2151-2153. (Pubitemid 32591717)
48. Minassian B, Huczko E, Washo T, et al. In vitro activity of ravuconazole against zygomycetes, Scedosporium and Fusarium isolates. Clin Microbiol Infect 2003; 9:1250-1252. (Pubitemid 38028881)
49. Hata K, Kimura J, Miki H, et al. Efficacy of ER-30346, a novel oral triazole antifungal agent, in experimental models of aspergillosis, candidiasis, and cryptococcosis. Antimicrob Agents Chemother 1996; 40:2243-2247. (Pubitemid 26328023)
50. Hata K, Kimura J, Miki H, et al. In vitro and in vivo antifungal activities of ER-30346, a novel oral triazole with a broad antifungal spectrum. Antimicrob Agents Chemother 1996; 40:2237-2242. (Pubitemid 26328022)
51. Petraitis V, Petraitiene R, Sarafandi AA, et al. Combination therapy in treatment of experimental pulmonary aspergillosis: synergistic interaction between an antifungal triazole and an echinocandin. J Infect Dis 2003; 187:1834-1843. (Pubitemid 36724481)
52. Morera-Lopez Y, Torres-Rodriguez JM, Jimenez-Cabello T, Baro-Tomas T. Cryptococcus gattii: in vitro susceptibility to the new antifungal albaconazole versus fluconazole and voriconazole. Med Mycol 2005; 43:505-510. (Pubitemid 41700943)
53. Trilles L, Fernandez-Torres B, Lazera MS, et al. In vitro antifungal susceptibility of Cryptococcus gattii. J Clin Microbiol 2004; 42:4815-4817. (Pubitemid 39362411)
54. Ramos G, Cuenca-Estrella M, Monzon A, Rodriguez-Tudela JL. In vitro comparative activity of UR-9825, itraconazole and fluconazole against clinical isolates of Candida spp. J Antimicrob Chemother 1999; 44:283-286. (Pubitemid 29389293)
55. Capilla J, Ortoneda M, Pastor FJ, Guarro J. In vitro antifungal activities of the new triazole UR-9825 against clinically important filamentous fungi. Antimicrob Agents Chemother 2001; 45:2635-2637. (Pubitemid 32801923)
56. Pappas PG, Kauffman CA, Andes D, et al. Clinical practice guidelines for the management of candidiasis: 2009 update by Infectious Diseases Society of America. Clin Infect Dis 2009; 48:503-535.
57. CornelyOA, Bassetti M, Calandra T, et al. ESCMID guideline for the diagnosis and management of Candida diseases 2012: nonneutropenic adult patients. Clin Microbiol Infect 2012; 18 (Suppl 7):19-37.
58. Ruhnke M, Paiva JA, Meersseman W, et al. Anidulafungin for the treatment of candidaemia/invasive candidiasis in selected critically ill patients. Clin Microbiol Infect 2012; 18:680-687.
59. Kett DH, Shorr AF, Reboli AC, et al. Anidulafungin compared with fluconazole in severely ill patients with candidemia and other forms of invasive candidiasis: support for the 2009 IDSA treatment guidelines for candidiasis. Crit Care 2011; 15:R253.
60. Dupont BF, Lortholary O, Ostrosky-Zeichner L, et al. Treatment of candidemia and invasive candidiasis in the intensive care unit: post hoc analysis of a randomized, controlled trial comparing micafungin and liposomal amphotericin B. Crit Care 2009; 13:R159.
61. DiNubile MJ, Lupinacci RJ, Strohmaier KM, et al. Invasive candidiasis treated in the intensive care unit: observations from a randomized clinical trial. J Crit Care 2007; 22:237-244. (Pubitemid 47380232)
62. Roch A, Woloch C, Blayac D, et al. Effect of fluid loading during hypovolemic shock on caspofungin pharmacokinetic parameters in pig. Crit Care 2011; 15:R219.
63. Najvar L, Bocanegra R, Olivo M, Molina D. Once is enough: single dose aminocandin therapy of candidemia [abstract]. In: Program and abstracts of the 45th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC); 16-19 December 2005; Washington, DC. American Society for Microbiology; 2005:abstr. F-496.
64. Denning DW. Echinocandin antifungal drugs. Lancet 2003; 362:1142-1151. (Pubitemid 37222342)
65. Moore CB, Denning DW. In vitro activity of HMR3270 against Candida spp [abstract]. In: Program and abstracts of the 41st Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC); 16-19 December 2001; Chicago, IL. Washington, DC: American Society for Microbiology. 2001: abstr. F-2147.
66. Dromer F, Abdoul L, Improvisi L, et al. In vitro activity of HMR 3270 against yeasts and filamentous fungi. In: Program and abstracts of the 41st Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC); 16-19 December 2001; Chicago, IL. Washington, DC: American Society for Microbiology. 2001: abstr. F-2148.
67. Warn P, Sharp A, Denning DW. In vitro activity of the echinocandin HMR3270 against Aspergillus spp. In: Program and abstracts of the 41st Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC); 16-19 December 2001; Chicago, IL. Washington, DC: American Society for Microbiology. 2001: abstr. J-114.
68. Brzankalski G, Bocanegra R, Najvar L, Olivo M. Efficacy of aminocandin in treatment of Candida glabrata in mice. In: Program and abstracts of the 45th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC); 16-19 December 2005; Washington, DC: American Society for Microbiology; 2005: abstr. F-1624.
69. Isham N, Ghannoum MA. Determination of MICs of aminocandin for Candida spp. and filamentous fungi. J Clin Microbiol 2006; 44:4342-4344. (Pubitemid 44937061)
70. Sandage B, Cooper G, Najarian N, Lowther J. Pharmacokinetics and fungicidal activity of aminocandin (HMR3270), a novel echinocandin in healthy volunteers. In: Abstracts of the Fifteenth European Congress of Clinical Microbiology and Infectious Diseases; Copenhagen, Denmark; 2005. p.1115.
71. Najvar LK, Bocanegra R, Wiederhold NP, et al. Therapeutic and prophylactic efficacy of aminocandin (IP960) against disseminated candidiasis in mice. Clin Microbiol Infect 2008; 14:595-600. (Pubitemid 351639075)
72. Ghannoum MA, Kim HG, Long L. Efficacy of aminocandin in the treatment of immunocompetent mice with haematogenously disseminated fluconazoleresistant candidiasis. J Antimicrob Chemother 2007; 59:556-559. (Pubitemid 47073466)
73. Brzankalski GE, Najvar LK, Wiederhold NP, et al. Evaluation of aminocandin and caspofungin against Candida glabrata including isolates with reduced caspofungin susceptibility. J Antimicrob Chemother 2008; 62:1094-1100.
74. Peláez F, Cabello A, Platas G, et al. The discovery of enfumafungin, a novel antifungal compound produced by an endophytic Hormonema species biological activity and taxonomy of the producing organisms. Syst Appl Microbiol 2000; 23:333-343.
75. Spellberg B, Andes D, Perez M, et al. Safety and outcomes of open-label deferasirox iron chelation therapy for mucormycosis. Antimicrob Agents Chemother 2009; 53:3122-3125.
76. Spellberg B, Ibrahim AS, Chin-Hong PV, et al. The Deferasirox-AmBisome Therapy for Mucormycosis (DEFEAT Mucor) study: a randomized, doubleblinded, placebo-controlled trial. J Antimicrob Chemother 2012; 67:715-722.
77. Clemons KV, Stevens DA. Efficacy of nikkomycin Z against experimental pulmonary blastomycosis. Antimicrob Agents Chemother 1997; 41:2026-2028. (Pubitemid 27383251)
78. Goldberg J, Connolly P, SchnizleIn-Bick C, et al. Comparison of nikkomycin Z with amphotericin B and itraconazole for treatment of histoplasmosis in a murine model. Antimicrob Agents Chemother 2000; 44:1624-1629. (Pubitemid 30340805)
79. Hector RF, Zimmer GL, Pappagianis D. Evaluation of nikkomycins X and Z in murine models of coccidioidomycosis, histoplasmosis, and blastomycosis. Antimicrob Agents Chemother 1990; 34:587-593. (Pubitemid 20122287)
80. Sandovsky-Losica H, Shwartzman R, Lahat Y, Segal E. Antifungal activity against Candida albicans of nikkomycin Z in combination with caspofungin, voriconazole or amphotericin B. J Antimicrob Chemother 2008; 62:635-637.
81. Li RK, Rinaldi MG. In vitro antifungal activity of nikkomycin Z in combination with fluconazole or itraconazole. Antimicrob Agents Chemother 1999; 43:1401-1405. (Pubitemid 29259333)
82. Ganesan LT, Manavathu EK, Cutright JL, et al. In vitro activity of nikkomycin Z alone and in combination with polyenes, triazoles or echinocandins against Aspergillus fumigatus. Clin Microbiol Infect 2004; 10:961-966. (Pubitemid 39562462)
83. Stevens DA. Drug interaction studies of a glucan synthase inhibitor (LY 303366) and a chitin synthase inhibitor (nikkomycin Z) for inhibition and killing of fungal pathogens. Antimicrob Agents Chemother 2000; 44:2547-2548. (Pubitemid 30650914)